We are looking forward to The Annual Scientific Conference on Sickle Cell and Thalassaemia, 2020, an unprecedented year in a number of ways; firstly by working in collaboration with the European Heamatology Association (EHA) and the British Society of Haematology (BSH) to host this year’s conference; and also as a result of Covid -19 we are embarking on an online virtual programme of events from 26th to 31st October with a face to face element in the final days, which due to the unpredictable nature of this pandemic means that we will need to review these plans regularly.

We would like to express our sympathy to those who have been impacted in anyway by the Covid-19 pandemic.

On behalf of EHA and BSH, I would like to acknowledge the collective efforts and work that has been done to keep our patients and families safe. This year’s conference may in time turn out to provide a new and improved forum for us to come together to share best practice and develop strategies for the future.  I will therefore like to introduce this year’s theme :

‘Haemoglobinopathies: Emerging Challenges and Future Therapies’

This theme reflects the rapid progress in research for new drug therapies and curative therapies; a number of FDA approvals and other national approval process are at different stages. The fact that the majority of patients with Sickle Cell Disease and Thalassemia live in low resource settings these new therapies may not be readily accessible or affordable, means that we must therefore refocus our attention to improve newborn screening and comprehensive care, hydroxyurea therapy, blood transfusion and effective iron chelation.

I am excited to be working with an expanded steering committee which includes renowned experts in Sickle Cell Disease, Thalassaemia and Psychology. Keep an eye out over the coming week for details on this year’s exciting new conference programme!

You are now invited now to submit abstracts for ASCAT/EHA/BSH 2020 conference, and all selected abstracts will be published in HemaSphere (EHA) journal.  We will also have a strong patient forum following on from last year’s priority setting session.

Kind Regards,

Professor Baba Inusa (Founder of ASCAT)

Register Here

Find Out More About This Year’s Programme

 

Welcoming Abstract Submission: ASCAT/EHA/BSH Conference 2020

We are pleased to invite you now to submit abstracts for this year’s conference, and also announce that selected abstracts will be published in HemaSphere (EHA).

Abstract Themes and Categories

  • Basic sciences and emerging therapies
  • Psychology, QOL and patient outcomes
  • Clinical and community implementation research
  • Public Health and Health Education
  • Aging and Haemoglobinopathies
  • Other aspects of Haemoglobinopathies

Abstract Submission Deadline Extension: ASCAT/EHA/BSH Conference 2020

The final deadline for abstract and poster submissions for this year’s conference is Friday 11th September 2020. Abstracts received after this date cannot be accepted.

Selected abstracts will be published in Hemisphere (EHA).

Submit your abstract today!